Home › NCT06575868
Myo-inositol During Pregnancy to Prevent Gestational Diabetes
Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial
Who can join
Ages 18 to 45 · Women
Full eligibility criteria
Inclusion Criteria: Singleton gestations Women aged \> 18 years and \< 45 years Recruited before 16 weeks gestation Obese (pre-pregnancy BMI ≥ 30) Receiving prenatal care at Tufts Medical Center Planning to give birth at Tufts Medical Center Can tolerate glucose tolerance test Willing and able to wear CGM Willing and able to sign informed consent Exclusion Criteria: Multiple gestation Preexisting diabetes Taking medications that impact body weight or metabolism (eg metformin) Inability to tolerate glucose tolerance test Adults unable to consent (cognitively impaired adults) Wards of the state Non-viable neonates Neonates of uncertain viability
About the study
Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).
This is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.
What is being tested
- Myo-inositol (dietary supplement)
- Myo-inositol placebo (dietary supplement)
Sponsor: Tufts Medical Center · Participants: 40 · Started: Mar 1, 2025
Contact the study team
- Zeinab Kassem, MD · Phone: 617-636-9897
Official record on ClinicalTrials.gov — NCT06575868
Locations in the U.S.
| Massachusetts | Tufts Medical Center, Boston |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.